Preliminary results of ZG005, a bispecific antibody targeting PD-1 and TIGIT, in combination with chemotherapy with or without bevacizumab as first-line treatment for advanced cervical cancer.

The failure is the latest stumble for a cancer drug class that hasn’t lived up to expectations. iTeos will begin a strategic review in response.

The Arcus anti-TIGIT molecule is also differentiated from Roche’s tiragolumab given use of Fc-inactive domain for its anti-TIGIT antibody which could enable better safety and tolerability, the ...

Roche announced that the Skyscraper-01 trial studying TIGIT antibody tiragolumab in combination with Roche's approved oncology drug Tecentriq in patients with PD-L1 positive non-small cell lung ...

The anti-TIGIT therapy, vibostolimab, plus Keytruda and chemotherapy did not improve overall survival versus Tecentriq plus chemotherapy in extensive-stage small cell lung cancer.

Merck is working on different strategies to drive the long-term growth of Keytruda. These include innovative immuno-oncology combinations, including Keytruda with TIGIT, LAG3 and CTLA-4 inhibitors.

While TIGIT was once hyped as the next great immunotherapy target, a number of failed trials has cooled that sentiment, and some drugmakers have pared their TIGIT programs.

But TIGIT has not lived up to the hype, at least not yet. The most recent setback occurred just last week, when Roche reported the failure of its anti-TIGIT antibody in a Phase 3 study involving ...

Roche's (RHHBY) lung cancer drug tiragolumab fails in a clinical trial, hurting the shares of its rival anti-TIGIT developers, Compugen and Arcus. Read more here.

Gilead and Arcus Announce Anti-TIGIT Domvanalimab Plus Zimberelimab and Chemotherapy Exceeded One Year of Median Progression-Free Survival as a First-Line Treatment for Upper GI Cancers ...